Wynn, Jonathan K. http://orcid.org/0000-0002-1763-8540
Green, Michael F.
Hellemann, Gerhard http://orcid.org/0000-0003-2449-7704
Reavis, Eric A.
Marder, Stephen R. http://orcid.org/0000-0003-0288-309X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH107564, MH107564, MH107564, MH107564, MH107564)
Article History
Received: 7 March 2018
Revised: 13 July 2018
Accepted: 19 July 2018
First Online: 28 July 2018
Competing interests
: Dr. Marder has served as a consultant to Roche, Allergan, Takeda, Neurocrine, Newron, Boeringer-Ingelheim, Otsuka, Acadia, Lundbeck, and Teva. He has received research support from Neurocrine and Takeda. Dr. Green has been a consultant to AiCure, Lundbeck, and Takeda, and he is on the scientific board of Cadent. He has received research funds from FORUM. The remaining authors declare no competing interests.